Abdullah Khalid, MD
Pulmonary Disease · Portland, ORNPI 1811239981
Payments from drug & device makers
What this record shows
Inspire Medical Systems, Inc. accounts for 70.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $1,972 and has fallen 95.2% since, to $94 in 2025.
Across 42 payments — averaging $58.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$2K
- AbbVie$215
- ZOLL Respicardia, Inc.$178
- Boehringer Ingelheim$84
- Johnson & Johnson$75
- AstraZeneca$26
- plus $140 from 7 others
What the payments were for
- Travel & lodging$1,14847%
- Food & beverage$1,31853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 13 | $1,747 |
| AbbVie(2 entities) | 11 | $215 |
| ZOLL Respicardia, Inc. | 1 | $178 |
| Boehringer Ingelheim | 4 | $84 |
| Johnson & Johnson | 4 | $75 |
| AstraZeneca | 2 | $26 |
| Lilly USA, LLC | 1 | $25 |
| Abbott | 1 | $22 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Eisai Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$1,571
- remede System$178
How this compares
$2,466 in reported general payments places this provider in the 70th percentile of 154 pulmonary disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Portland
- Stephen YauPortland$984K
- Matthew DrakePortland$135K
- Peter LeePortland$98K
- Jordan FeinPortland$87K
- Granthem FarrPortland$66K
- David HotchkinPortland$65K
- Jeffrey RobinsonPortland$51K
- Steven SearsPortland$21K
- Melvin MorganrothPortland$14K
- Christina MacrostyPortland$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.